Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review

doi:10.1016/j.ajur.2018.01.001

Asian Journal of Urology, 2019, 6 (2): 210-214 doi: 10.1016/j.ajur.2018.01.001

Case Report

Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review

Fangyuan Zhang^a,1,Gang Zhao^b,1,Pengjie Wu^a,Qi An^b,Yang Yang^b,Xin Chen^a,Jianye Wang^a,Dong Wei^a,*(

)

a. Department of Urology, Beijing Hospital, The Fifth Clinical Medical School of Peking University,National Center of Gerontology, Beijing, China
b.Department of General Surgery, Beijing Hospital, The Fifth Clinical Medical School of Peking University, National Center of Gerontology, Beijing, China

Abstract
Related Citation (12)

Download:

HTML

PDF (1323KB)
Export: BibTeX | EndNote (RIS)

Abstract

Sigmoid metastasis of renal cell carcinoma (RCC) is very rare. Herein we report a case of pathologically proven asynchronous abdominal wall and sigmoid metastases after a right nephrectomy. An 84-year-old man underwent right radical nephrectomy for clear cell renal cell carcinoma (ccRCC) 13 years ago. Solitary contralateral abdominal wall metastasis was found for left abdominal mass 9 years after nephrectomy. The man experienced melena underwent resection of sigmoid colon tumor in February, 2016. The postoperative pathological examinations revealed that the tumors were metastases of ccRCC. Recurrence more than 5 years after nephrectomy has been accepted as late recurrence by the majority of urologists now. Late recurrence is one of the specific biological behaviors of RCC. Asynchronous late recurrence of abdominal wall and sigmoid metastases in ccRCC has not been reported before. When patients have sigmoid mass after nephrectomy for RCC, doctors may consider the possibility of late recurrence.

Key words： Sigmoid metastasis Late recurrence Renal cell carcinoma Asynchronous metastases Abdominal wall metastasis

Received: 03 January 2017 Available online: 06 January 2018

Corresponding Authors: Fangyuan Zhang,Gang Zhao,Dong Wei E-mail: dongwei63@yeah.net

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Fangyuan Zhang
	Gang Zhao
	Pengjie Wu
	Qi An
	Yang Yang
	Xin Chen
	Jianye Wang
	Dong Wei

TRENDMD:

Cite this article:

Fangyuan Zhang,Gang Zhao,Pengjie Wu, et al. Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review[J]. Asian Journal of Urology, 2019, 6(2): 210-214.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2018.01.001 OR http://www.ajurology.com/EN/Y2019/V6/I2/210

[1]	H. Cohen ,F. Mc.GovernRenal cell carcinoma.N Engl J Med, 353(2005), pp. 2477-2490.
[2]	A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward ,D. Forman.Global cancer statistics.CA Cancer J Clin, 61(2011), pp. 69-90.
[3]	B.I. Rini, S.C. Campbell ,B. Escudier.Renal cell carcinoma.The Lancet, 373(2009), pp. 1119-1132.
[4]	B.J. Thibodeau, M. Fulton, L.E. Fortier, T.J. Geddes, B.L. Pruetz, S. Ahmed , et al.Characterization of clear cell renal cell carcinoma by gene expression profiling. Urol Oncol,34(2016),http://doi.org/10.1016/j.urolonc.2015.11.001.168.e1-9
[5]	D.W. McNichols, J.W. Segura, J.H. DeWeerd .Renal cell carcinoma: long-term survival and late recurrence.J Urol(1981), pp. 12617-12623.
[6]	H. Tapper, H. Klein, W. Rubenstein, L. Intriere, Y. Choi, E. Kazam , et al.Recurrent renal cell carcinoma after 45 years.Clin Imaging Recurrent renal cell carcinoma after 45 years.Clin Imaging ( 1997), pp. 21273-21275.
[7]	N. Kroeger, T.K. Choueiri, J.L. Lee, G.A. Bjarnason, J.J. Knox, M.J. MacKenzie , et al.Survival outcome Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol(2014), pp. 651086-651092.
[8]	C. Grüllich, S. Vallet, C. Hecht, S. Duensing, B. Hadaschik, D. Jager, et al.Local salvage therapy for late (≥2 years ) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence.Urol Oncol, 34(2016),http://doi.org/10.1016/j.urolonc.2015.11.022.238.e9-17
[9]	B. Ljungberg, F.I. Alamdari, T. Rasmuson , G. Roos.Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy.BJU Int( 1999), pp. 84405-84411.
[10]	Y. Fujii, M. Ikeda, K. Kurosawa, M. Tabata, T. Kamigaito, C. Hosoda , et al.Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.Int J Clin Oncol, 20(2015), pp. 802-807.
[11]	A. Kassabian, J. Stein, N. Jabbour, K. Parsa, D. Skinner, D. Parekh , et al.Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature.Urology, 56(2000), pp. 211-215.
[12]	N. Pathe, J. Raymond , A.U.Cintra.Metastatic renal cell cancer presenting as a breast mass.Clin Adv Hematol Oncol, 10(2012), pp. 124-126.
[13]	M. Onorati, G. Petracco, P. Uboldi, D.G. Redaelli, S. Romagnoli, M. Albertoni , et al.A solitary polypoid gastric metastasis 20 years after renal cell carcinoma: an event to be considered, and a brief review of the literature.Pathologica, 105(2013), pp. 132-136.
[14]	S.D. Brookman-May, M. May, S.F. Shariat, G. Novara, R. Zigeuner, L. Cindolo, et al. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma — results from a comprehensive multi-centre database (CORONA/SATURN-Project). BJU Int, 112(2013), pp. 909-916.
[15]	S.P. Kim, C.J. Weight, B.C. Leibovich, R.H. Thompson, B.A. Costello, J.C. Cheyille , et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology, 78(2011), pp. 1101-1106.
[16]	M. Santoni, A. Conti, C. Porta, G. Procopio, C.N. Sternberg, U. Basso , et al.Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.J Urol, 193(2015), pp. 41-47.
[17]	I.J.Fidler The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 3(2003), pp. 453-458.
[18]	E. Nakano, H. Fujioka, M. Matsuda, M. Osafune, M. Takaha , T. Sonoda.Late recurrence of renal-cell carcinoma after nephrectomy.Eur Urol, 10(1984), pp. 347-349.
[19]	A. Adamy, K.T. Chong, D. Chade, J. Costaras, G. Russo, M.G. Kaag , et al.Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma.J Urol, 185(2011), pp. 433-438.
[20]	B. Ljungberg, K. Bensalah, S. Canfield, S. Dabestani, F. Hofmann, M. Hora , et al.EAU guidelines on renal cell carcinoma:EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol, 67(2015), pp. 913-924.
[21]	R.J. Motzer, J. Bacik, B.A. Murphy, P. Russo ,M. Mazumdar. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.J Clin Oncol, 20(2002), pp. 289-296.
[22]	D.F. McDermott, M.M. Regan, J.I. Clark, L.E. Flaherty, G.R. Weiss, T.F. Logan, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.J Clin Oncol, 23(2005), pp. 133-141.
[23]	J. Bellmunt, S. Négrier, B. Escudier, A. Awada, M. Aapro ,SIOG T.The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol, 69(2009), pp. 64-72.
[24]	C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstass , et al.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.J Clin Oncol, 28(2010), pp. 1061-1068.
[25]	R.J. Motzer, B. Escudier, P. Tomczak, T.E. Hutson, M.D. Michaelson, S. Negrier , et al.Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.Lancet Oncol, 14(2013), pp. 552-562.
[26]	T.K. Choueiri, B. Escudier, T. Powles, N.M. Tannic, P.N. Mainwaring, B.I. Rini , et al.Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Lancet Oncol, 17(2016), pp. 917-927.
[27]	B. Escudier, A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik , et al.Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.Lancet, 370(2007), pp. 2103-2111.
[28]	C. Coppin.Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.Biologics, 4(2010), pp. 91-101.
[29]	C. Messina, A. Di Meglio, P.V. Nuzzo, F. Boccardo ,F. Ricci.Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.Tumori, 101(2015), pp. e79-e81,http://doi.org/10.5301/tj.5000268
[30]	J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu , et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med, 366(2012), pp. 2455-2465.
[31]	O. Bozkurt, I. Hac?bekiroglu, M.A. Kaplan, Y. Duzkopru, M. Uysal, H. Karaca , et al.Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients?.Clin Genitourin Cancer, 13(2015), pp. 548-554.
[32]	Y.H. Park, K.D. Baik, Y.J. Lee, J.H. Ku, H.H. Kim, C. Kwak. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis.BJU Int,110( 2012), pp. E553-E558,http://doi.org/10.1111/j.1464-410X.2012.11246.x .